Navigation Links
Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
Date:8/1/2008

SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, at 11:15 a.m. Eastern Time at the Millennium Broadway Hotel in New York.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
2. Medivation Announces Senior Management Promotions
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
6. Cantel Medical Announces Management Succession at Crosstex Healthcare Disposables Subsidiary
7. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
8. Novavax Announces Closing of $18 Million Registered Direct Offering
9. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
10. Thermage, Inc. Announces Second Quarter 2008 Results Release Date and Conference Call
11. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
Breaking Biology News(10 mins):